Healthcare provider profile · identity verified

Homer Curtiss Merrick, M.D.

Internal Medicine · SEALEVEL, NC · NPI 1487600821

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Alprazolam	Alprazolam	201	27
Atorvastatin Calcium	Atorvastatin Calcium	143	31
Omeprazole	Omeprazole	123	33
Rosuvastatin Calcium	Rosuvastatin Calcium	109	34
Lorazepam	Lorazepam	89	12
Lisinopril	Lisinopril	85	26
Levothyroxine Sodium	Levothyroxine Sodium	78	19
Amlodipine Besylate	Amlodipine Besylate	77	23
Gabapentin	Gabapentin	72	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	69	20
Metoprolol Succinate	Metoprolol Succinate	59	19
Furosemide	Furosemide	58	17
Losartan Potassium	Losartan Potassium	57	15
Pantoprazole Sodium	Pantoprazole Sodium	56	17
Metoprolol Tartrate	Metoprolol Tartrate	55	14
Ozempic	Semaglutide	54	suppressed
Metformin Hcl	Metformin Hcl	48	11
Promethazine Hcl	Promethazine Hcl	47	suppressed
Trazodone Hcl	Trazodone Hcl	46	11
Albuterol Sulfate Hfa	Albuterol Sulfate	43	17
Potassium Chloride	Potassium Chloride	43	15
Escitalopram Oxalate	Escitalopram Oxalate	40	13
Tramadol Hcl	Tramadol Hcl	36	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	35	14
Enalapril Maleate	Enalapril Maleate	35	suppressed
Meloxicam	Meloxicam	35	14
Tamsulosin Hcl	Tamsulosin Hcl	35	12
Allopurinol	Allopurinol	34	11
Bupropion Xl	Bupropion Hcl	33	suppressed
Citalopram Hbr	Citalopram Hydrobromide	33	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	33	suppressed
Pravastatin Sodium	Pravastatin Sodium	33	suppressed
Azithromycin	Azithromycin	30	20
Ibuprofen	Ibuprofen	30	12
Esomeprazole Magnesium	Esomeprazole Magnesium	29	suppressed
Prazosin Hcl	Prazosin Hcl	28	suppressed
Sertraline Hcl	Sertraline Hcl	28	suppressed
Eliquis	Apixaban	26	suppressed
Pregabalin	Pregabalin	26	suppressed
Diclofenac Sodium	Diclofenac Sodium	25	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	25	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	24	13
Xarelto	Rivaroxaban	24	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	23	suppressed
Simvastatin	Simvastatin	23	suppressed
Celecoxib	Celecoxib	22	suppressed
Myrbetriq	Mirabegron	22	suppressed
Alendronate Sodium	Alendronate Sodium	21	suppressed
Methylprednisolone	Methylprednisolone	21	19
Shingrix	Varicella-Zoster Ge/As01b/Pf	21	13
Ropinirole Hcl	Ropinirole Hcl	20	suppressed
Fluticasone Propionate	Fluticasone Propionate	19	suppressed
Duloxetine Hcl	Duloxetine Hcl	18	suppressed
Fenofibrate	Fenofibrate	18	suppressed
Montelukast Sodium	Montelukast Sodium	18	suppressed
Clopidogrel	Clopidogrel Bisulfate	17	suppressed
Ezetimibe	Ezetimibe	17	suppressed
Nystatin	Nystatin	17	suppressed
Propranolol Hcl	Propranolol Hcl	17	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	17	suppressed
Chlorthalidone	Chlorthalidone	16	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Jardiance	Empagliflozin	16	suppressed
Bupropion Hcl	Bupropion Hcl	14	suppressed
Colchicine	Colchicine	14	suppressed
Linzess	Linaclotide	14	suppressed
Metformin Hcl Er	Metformin Hcl	13	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	13	suppressed
Symbicort	Budesonide/Formoterol Fumarate	13	suppressed
Torsemide	Torsemide	13	suppressed
Glimepiride	Glimepiride	12	suppressed
Meclizine Hcl	Meclizine Hcl	12	suppressed
Rybelsus	Semaglutide	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Temazepam	Temazepam	12	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	11	suppressed
Entresto	Sacubitril/Valsartan	11	suppressed
Eszopiclone	Eszopiclone	11	suppressed
Finasteride	Finasteride	11	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	11	suppressed
Sucralfate	Sucralfate	11	suppressed
Topiramate	Topiramate	11	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error